Public company intelligence preview
TUHURA BIOSCIENCES INC
9 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: N/A average total compensation across covered insiders.
Governance movement
Public aggregate: 1 governance events in the last year.
Institutional ownership
Public aggregate: 64 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
TuHURA Biosciences Inc. is a Healthcare sector, Biotechnology company focused on clinical-stage immuno-oncology. Its lead program, IFx-2.0, is in a Phase 3 trial for advanced or metastatic Merkel cell carcinoma, and the company also added TBS-2025 through its Kineta acquisition to pursue work in relapsed/refractory AML. The business is still pre-commercial, with no product revenue, and is heavily dependent on clinical outcomes, regulatory progress, manufacturing execution, and access to external capital. Its strategy centers on differentiated oncology assets that may address resistance to existing immunotherapies and other high-unmet-need cancer settings.
Executive Compensation Practices
For a clinical-stage biotechnology company like TuHURA Biosciences, executive compensation is typically tied less to near-term sales and more to clinical, regulatory, and financing milestones. Based on the filing summaries, the most relevant performance drivers are progression of the Phase 3 IFx-2.0 program, advancement of TBS-2025, successful completion of the Kineta acquisition integration, and maintaining sufficient liquidity to keep trials moving. Because R&D spending and stock-based compensation are meaningful parts of operating expenses, equity awards likely play a central role in aligning management with long-term shareholder value. In this sector, compensation packages often emphasize retention and milestone-based incentives, since clinical-stage biotech firms face high volatility and long development timelines.
Insider Trading Considerations
Insider trading patterns at TuHURA Biosciences may be strongly influenced by binary clinical and regulatory events, including FDA decisions, trial initiations, hold releases, and readouts from the IFx-2.0 and TBS-2025 programs. As a small biotech with limited cash and ongoing financing needs, insider activity may also cluster around capital raises, warrant exercises, merger-related events, and other financing windows that can affect dilution and valuation. The company’s dependence on third-party manufacturers, collaborations, and intellectual property makes material nonpublic information especially sensitive, so trading restrictions around clinical updates and partnership developments are likely important. For researchers and traders, any insider buying or selling should be viewed in the context of cash runway, trial progress, and whether upcoming milestones could materially reprice the stock.
Unlock the full HURA insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.